If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solution
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Cyramza® (ramucirumab) administered?
Administer diluted Cyramza (ramucirumab) as an intravenous infusion only. Do not administer as an intravenous push or bolus.
Calculation and Preparation of Ramucirumab for Administration
Visually inspect vials for particulate matter and discoloration. Discard if particulate matter or discolorations are identified.1
Calculate the dose and the required volume of ramucirumab needed for the calculated dose. Withdraw the required volume of ramucirumab and further dilute with only 0.9% sodium chloride injection in an intravenous (IV) infusion container to a final volume of 250 mL. Do not use dextrose-containing solutions.1
Do not shake. Gently invert the container to ensure adequate mixing. Do not dilute with other solutions or co-infuse with other electrolytes or medications.1
Do not freeze. Store diluted solution for no more than 24 hours at 2°C to 8°C (36°F to 46°F) or 4 hours at room temperature (below 25°C [77°F]).1
Administration of Ramucirumab
Administer ramucirumab as an IV infusion only. Do not administer ramucirumab as an IV push or bolus.1
Administer diluted ramucirumab solution via infusion pump through a separate infusion line. Use of a protein sparing 0.22 micron filter is recommended. Flush the line with sterile 0.9% sodium chloride Injection at the end of the infusion.1
If the first 60-minute infusion of ramucirumab is tolerated, then all subsequent infusions may be administered over 30 minutes. This applies to all recommended doses of ramucirumab and all approved indications.1
Discard any unused portion of ramucirumab.1
Enclosed Prescribing Information
Reference
1Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: January 28, 2025